Revisiting CCL22 in autoimmune diseases: pathogenesis and clinical implications

Area of Science:

• Immunology
• Molecular Biology
• Autoimmune Diseases

Background:

• CCL22 (macrophage-derived chemokine, MDC) is a CC chemokine that binds to its receptor CCR4.
• This interaction regulates immune cell trafficking, influencing both immune homeostasis and inflammation.

Purpose of the Study:

• To review the central roles of the CCL22-CCR4 axis in immune tolerance and inflammatory responses.
• To describe the regulation of CCL22-CCR4 functions by cell type, tissue microenvironment, and signaling states in autoimmune diseases.

Main Methods:

• Literature review of studies on CCL22 and CCR4 in immune regulation and autoimmune diseases.
• Analysis of the dual role of CCL22-CCR4 signaling in different tissue microenvironments.

Main Results:

• CCL22-CCR4 signaling is context-dependent, with varying effects in different autoimmune conditions.
• Under steady-state, CCL22 promotes immune tolerance by recruiting regulatory T-cells (Tregs).
• Down-regulation of CCL22 leads to insufficient Treg recruitment, causing immune dysregulation and tissue injury.

Conclusions:

• The CCL22-CCR4 axis is critical in the pathogenesis of autoimmune diseases like vitiligo, lupus, and type 1 diabetes.
• Fine-tuning of CCL22-CCR4 signaling by cellular and environmental factors is essential for maintaining immune balance.